Uchio Eiichi, Inoue Hirotoshi, Kadonosono Kazuaki
Department of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, Japan.
Korean J Ophthalmol. 2013 Jun;27(3):199-203. doi: 10.3341/kjo.2013.27.3.199. Epub 2013 May 7.
Antimicrobial peptides have an important role in self-protection of the ocular surface. Human cationic antimicrobial protein (hCAP)-18 is a linear, α-helical peptide that consists of a conserved pro-sequence called a cathelin-like domain and a C-terminal peptide named LL-37. We investigated the in vitro anti-adenoviral activity of hCAP-18/LL-37 in several adenovirus types, inducing keratoconjunctivitis.
A549 cells were used for viral cell culture, and human adenovirus (HAdV) types 3 (HAdV3, species B), 4 (species E), 8, 19a, and 37 (species D) were used. The cytotoxicity of LL-37 was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay to obtain 50% cytotoxic concentration. After pretreatment of A549 cells with serial dilutions of LL-37 for 24 hours, adenovirus was cultured for seven days, and adenoviral DNA was quantitatively measured by real-time polymerase chain reaction (PCR).
The 50% effective concentration of LL-37 obtained by real-time PCR ranged between 118 and 270 µM. LL-37 showed a significant inhibitory effect on adenoviral proliferation in all adenovirus types except HAdV4 in a dose-dependent manner.
LL-37 has significant inhibitory activity against HAdV3, 8, and 19, which induce keratoconjunctivitis. These results indicate that hCAP-18/LL-37 may be a possible candidate for the treatment of HAdV keratoconjunctivitis.
抗菌肽在眼表的自我保护中发挥重要作用。人阳离子抗菌蛋白(hCAP)-18是一种线性α螺旋肽,由一个称为类组织蛋白酶结构域的保守前序列和一个名为LL-37的C端肽组成。我们研究了hCAP-18/LL-37在几种引起角结膜炎的腺病毒类型中的体外抗腺病毒活性。
使用A549细胞进行病毒细胞培养,并使用3型(HAdV3,B种)、4型(E种)、8型、19a型和37型(D种)人腺病毒(HAdV)。通过3-(4,5-二甲基噻唑-2-基)-5-(3-羧甲氧基苯基)-2-(4-磺基苯基)-2H-四唑(MTS)测定法评估LL-37的细胞毒性,以获得50%细胞毒性浓度。用系列稀释的LL-37预处理A549细胞24小时后,培养腺病毒7天,并通过实时聚合酶链反应(PCR)定量测量腺病毒DNA。
通过实时PCR获得的LL-37的50%有效浓度在118至270μM之间。LL-37对除HAdV4外的所有腺病毒类型的腺病毒增殖均表现出显著的剂量依赖性抑制作用。
LL-37对引起角结膜炎的HAdV3、8和19具有显著的抑制活性。这些结果表明,hCAP-18/LL-37可能是治疗HAdV角结膜炎的潜在候选药物。